SCHEMBL17256744

SCHEMBL17256744

CC(=O)O/N=C(\C)c1nc(C#N)cs1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RBBP9 O75884 5/20 0.35
KMT2A Q03164 3/20 0.35
ALDH1A1 P00352 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CYP1A2 P05177 4/20 0.34
CYP2D6 P10635 4/20 0.34
CYP2C19 P33261 3/20 0.34
CASP3 P42574 2/20 0.34
SENP8 Q96LD8 2/20 0.34
SENP7 Q9BQF6 2/20 0.34
SENP6 Q9GZR1 2/20 0.34
MAPT P10636 2/20 0.33
HSD17B10 Q99714 1/20 0.32
CYP2C9 P11712 1/20 0.32
GRM1 Q13255 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17256745 1.00 RBBP9 (0.35) RBBP9KMT2AALDH1A1L3MBTL1CYP1A2
SCHEMBL17257489 0.83 HSD17B10 (0.34) MAPTHSD17B10
SCHEMBL17257490 0.83 HSD17B10 (0.34) MAPTHSD17B10
SCHEMBL12743239 0.77 ALDH1A1 (0.38) ALDH1A1CYP1A2CYP2D6MAPTHSD17B10
SCHEMBL17257057 0.74 MAPT (0.33) RBBP9KMT2AALDH1A1L3MBTL1CYP1A2
SCHEMBL17257372 0.74 ALDH1A1 (0.41) RBBP9KMT2AALDH1A1CYP1A2CYP2D6
SCHEMBL4777182 0.74 MYC (0.38) CYP1A2CYP2D6HSD17B10CYP2C9GRM1
SCHEMBL17257275 0.72 CYP1A2 (0.31) CYP1A2CYP2D6CYP2C9GRM1
SCHEMBL17257273 0.72 CYP1A2 (0.31) CYP1A2CYP2D6CYP2C9GRM1
SCHEMBL213731 0.67 RBBP9 (0.67) RBBP9KMT2AALDH1A1L3MBTL1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group BRIDGESTONE CORPORATION (JP) 2018-07-24 US claimed
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group BRIDGESTONE CORPORATION (JP) 2018-07-24 US disclosed
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORPORATION (JP) 2015-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group PAM, PPOX, MB RBBP9 1649/4885KMT2A 2399/4885ALDH1A1 3041/4885
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP PAM, PPOX, MB RBBP9 1649/4885KMT2A 2399/4885ALDH1A1 3041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.